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Abstract This article gives an overview on a number of
novel clinical trials in the ﬁeld of cardiovascular medicine,
which were presented during the Late Breaking Clinical
Trial Sessions at the 59th annual meeting of the American
College of Cardiology in Atlanta, USA, from 14th March
to 16th March 2010. The data were presented by leading
experts in the ﬁeld with relevant positions in the trials.
These comprehensive summaries should provide the read-
ers with the most recent data on diagnostic and therapeutic
developments in cardiovascular medicine similar as pre-
viously reported (Schirmer SH, van der Laan AM, Bohm
M, Mahfoud F in Clin Res Cardiol 98:691–699, 2009;
Maier LS, Schirmer SH, Walenta K, Jacobshagen C, Bohm
M in Clin Res Cardiol 98:413–419, 2009).
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ACCORD
In June 2001 the ACCORD (The Action to Control Car-
diovascular Risk in Diabetes) study was started to answer
three burning questions for diabetic patients:
1. Is more intensive blood glucose lowering strategy
(targeting a glycated hemoglobin level below 6.0%)
superior to less aggressive therapy (targeting a level
from 7.0 to 7.9%)?
2. Is a combination therapy with a statine plus a ﬁbrate
more beneﬁcial than a statin monotherapy?
3. Can an intensive blood pressure lowering therapy
(targeting normal systolic blood pressure values, i.e.,
\120 mmHg) be more successful in preventing car-
diovascular endpoints than a standard therapy targeting
systolic blood pressure of less than 140 mmHg?
In order to answer these three questions, a double 2 9 2
factorial design was used (Fig. 1). 10,251 patients with
diabetes mellitus (median HbA1c of 8.1%) and either a
cardiovascular disease or at least two additional risk factors
were recruited in 77 clinical centers across the United
States and Canada, a clinical trial which was sponsored by
the National Heart, Lung, and Blood Institute (NHLBI).
After a mean duration of follow-up of 3.5 years, a glucose
control arm of the study was discontinued: Although the
primary endpoint, i.e., the composite of nonfatal myocar-
dial infarction, nonfatal stroke, or death from cardiovas-
cular cause, showed no signiﬁcant difference, death from
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in the intensive-therapy group. These results were pub-
lished in 2008 [3]. In the ﬁrst late breaking clinical trial
session of the ACC 2010 in Atlanta/USA the two ongoing
ACCORD studies were presented.
ACCORD lipid study
Henry Ginsberg (Columbia University College of Physi-
cian Surgeons, New York) reported on the result of the
lipid lowering arm (Fig. 1). In this arm of the trial, patients
were randomized to fenoﬁbrate (starting dose 160 mg) and
placebo in addition to open-labeled simvastatin [4]. This
treatment had no signiﬁcant effect on LDL-cholesterol as
compared to placebo, but signiﬁcantly increased HDL-
cholesterol by about 1 mg/dl and signiﬁcantly decreased
triglycerides by 26 mg/dl as compared to placebo,
respectively. This change was achieved in diabetic patients
with a baseline of a median value of 162 mg/dl triglycer-
ide. The treatment was safe as shown by creatine kinase as
well as liver enzymes measurements. Although there was a
slight increase in the serum creatinine levels, no increase
was seen regarding the incidence of both hemodialysis and
endstage renal disease. In contrast, there was a lower
incidence of microalbuminuria and macroalbuminuria in
the treatment group. Signiﬁcant changes were observed
neither in the primary endpoint (nonfatal myocardial,
nonfatal stroke, and death of cardiovascular cause) nor in
the secondary endpoints. Only in a subgroup of patients,
who had a triglycerides level of more than 204 mg/dl and
an HDL-cholesterol level of less than 34 mg/dl, a tendency
(P = 0.057) for a reduction of the primary endpoint
(-28%) was observed. The following conclusions can be
made from the results and the vivid discussion:
1. Combination therapy of simvastatin and fenoﬁbrate is
safe.
2. General treatment of all diabetic patients with simva-
statin plus fenoﬁbrate cannot be recommended.
3. Patients with high triglycerides and low HDL-choles-
terol may beneﬁt from such a combination therapy.
Whether this is true has to be investigated in a separate
trial (presenter: Henry Ginsberg, New York, USA).
ACCORD blood pressure trial
In the second presentation of the late breaking clinical
trials session, W.C. Cushmann (Veterans Affairs Medical
Center, Memphis, Tennessee) presented the results of the
intensive blood-pressure control arm of the ACCORD
study. In this study arm (Fig. 1), 4,733 patients were ran-
domly assigned to an intensive therapy with a target sys-
tolic blood pressure of less than 120 mmHg or a standard
antihypertensive regime targeting a systolic blood pressure
of 140 mmHg [5]. The mean follow-up was 4.7 years. The
ACCORD blood pressure trial was a nonblinded trial;
patients in the standard-therapy groups had a lower expo-
sure to antihypertensive drugs (2.1) as compared to the
intensive-therapy group (3.4). This resulted in a decrease of
systolic blood pressure with an average between groups
difference of 14.2 mmHg. The average diastolic blood
difference was 6.1 mmHg. Regarding safety, the intensive-
therapy groups had signiﬁcantly more adverse events:
higher rates of hypokalemia and increase in serum creati-
nine, although symptoms of orthostatic hypotension were
similar between the two groups. The primary outcome,
again the composite of nonfatal myocardial infarction,
nonfatal stroke, and cardiovascular death, was not signiﬁ-
cantly different between the two treatment groups. Also, no
signiﬁcant differences were found for the secondary out-
comes nonfatal infarction and death from cardiovascular
disease, whereas the difference in the rate of nonfatal
stroke was signiﬁcant (P\0.03) in favor of the more
intensive treatment. The following conclusions were drawn
from these results and discussed:
1. In diabetic patients a systolic blood pressure target of
120 mmHg is not superior in preventing major
cardiovascular events as compared to a target of
140 mmHg.
2. The ﬁnding that intensive blood pressure control may
reduce nonfatal (and fatal) stroke is in accordance with
two metaanalyses [6, 7]. However, assuming the result
would be real, the number needed to treat to prevent
one stroke over the course of 5 years was 89.
3. Regarding serious adverse events, patients treated
more intensively showed more often hyperkalemia,
increase in creatinine, and decrease in glomerular
ﬁltration rate (presenter: William C. Cushman, Mem-
phis, USA). Fig. 1 ACCORD. 2 9 2 factorial design
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A further blood-pressure trial was presented by Rhonda
Cooper-Dehoff (University of Florida, Gainesville, USA):
rethinking lower blood-pressure goals for diabetics with
documented coronary artery disease—ﬁndings from the
INVEST (INternational VErapamil SR, Trandolapril)
study. This study was undertaken because evidence which
supports systolic blood pressure values of less than
130 mmHg is lacking especially in diabetic patients with
coronary artery disease. In the overall INVEST-trial 22,576
patients participated. From these CAD patients, 6,400
patients suffered from diabetes and were included in the
presented subgroup analysis. Blood pressure control was
achieved by randomization to verapamil SR, trandalopril,
and HCT or atenolol, HCT and trandalopril with tranda-
lopril recommended to diabetic patients. Patients were
divided into three groups according to their mean on-
treatment systolic blood pressure: the tight control group
with values lower than 130 mmHg, the usual control
groups with values higher than 130 mmHg and lower than
140 mmHg, and the not controlled group with values
higher than 140 mmHg. The primary outcome, i.e., the
composite of all-cause mortality, nonfatal myocardial
infarction or nonfatal stroke, was highest in the not con-
trolled group (19.8%), and signiﬁcantly (P\0.0001)
lower in the usual control group (12.6%) and the tight
control group (12.7%; Table 1). Interestingly, all-cause
mortality was signiﬁcantly (\0.031) higher in the tight
control group as compared to the usual control group
(Table 1). In addition, an analysis was performed for
patients with systolic blood pressure lower than 120 mmHg
showing the highest all-cause mortality in the group with
lowest systolic blood pressure (hazard ratio above 2.0 when
systolic blood pressure was lower than 110 mmHg) (pre-
senter: Rhonda M. Cooper-Dehoff, Gainesville, USA).
NAVIGATOR
Robert Califf (Duke University, Durham, NC) reported on
the NAVIGATOR (NAteglinide and Valsartan in Impaired
Glucose Tolerance Outcomes Research) trial; it is neither
known of whether the short acting insulin secretagogue
nateglinide nor angiotensin-receptor-blocker valsartan may
reduce the risk to develop diabetes and cardiovascular
events in patients with impaired glucose tolerance (so-
called prediabetes) [8, 9]. In the presented trial, 9,306
participants with impaired glucose tolerance and cardio-
vascular disease or risk factors were assigned to receive
nateglinide (up to 60 mg three times daily) or placebo in a
2 9 2 factorial design with valsartan or placebo. The
median follow-up was 5.0 years for the development of
diabetes and 6.5 years for vital status. The primary out-
comes were development of diabetes and the composite of
death of cardiovascular causes, nonfatal myocardial
infarction, nonfatal stroke, or hospitalization for heart
failure. Nateglinide had no effect, neither on the develop-
ment of diabetes nor on cardiovascular events. In contrast,
valsartan showed a signiﬁcant (P\0.001) effect by
reducing the incidence of diabetes by 14% (Fig. 2), but did
not reduce the rate of cardiovascular events. The effect on
diabetes is in accordance with the LIFE [10] and the
VALUE [11] studies in which the incidence of diabetes
development, however, was a secondary endpoint (pre-
senter: Robert M. Califf, Durham, USA).
Table 1 INVEST: outcome rates
Outcome Tight control (n = 2,255) Usual control
(n = 1,970)
Not controlled
(n = 2,175)
P value
No. of events (events rate %)
INVEST follow-up (n = 6,400)
Primary outcome 286 (12.7) 249 (12.6) 431 (19.8) \0.0001
Nonfatal MI 29 (1.3) 33 (1.7) 67 (3.1) 0.008
Nonfatal stroke 22 (1.0) 26 (1.3) 52 (2.4) 0.001
Total MI 108 (4.8) 100 (5.0) 185 (8.5) \0.0001
Total stroke 34 (1.5) 33 (1.7) 70 (3.2) 0.0001
All-cause mortality 248 (11.0) 201 (10.2) 334 (15.4) \0.0001
Outcome Tight control (n = 1,389) Usual control
(n = 1,423)
Not allowed
(n = 1,558)
P value
No. of events (events rate %)
Extended follow-up (n = 4,370)
All-cause mortality 270 (19.4) 259 (18.2) 370 (23.7) 0.01
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Guidelines recommend strict rate control in patients with
permanent atrial ﬁbrillation (AF), but this is not based on
clinical evidence. RACE II (Rate Control Efﬁcacy in Per-
manent Atrial Fibrillation: a Comparison between Lenient
versus Strict Rate Control II) was a prospective, multi-
center, randomized, open-label, noninferiority trial
designed to compare two rate-control strategies in patients
with permanent AF [12]. 614 patients were assigned to
undergo a lenient rate-control strategy (resting heart
rate\110 beats per minute) or a strict rate-control strategy
(resting heart rate\80 beats per minute and heart rate
during moderate exercise\110 beats per minute). The
primary outcome was a composite of death from any cause,
hospitalization for heart failure, and stroke, systemic
embolism, bleeding, and life-threatening arrhythmic
events. To achieve the target heart rates, patients were
given beta-blockers, calcium-channel blockers and/or
digoxin. During follow-up ranging from 2 to 3 years, the
primary outcome occurred in 12.9% of patients in the
lenient-control group, as compared with 14.9% of patients
in the strict-control group (P\0.0001 for the prespeciﬁed
noninferiority margin; Fig. 3). More patients in the lenient-
control group met the heart rate targets (97.7 vs. 67.0% in
the strict-control group; P\0.001) with fewer total visits
(75 vs. 684; P\0.001). In conclusion, lenient rate control
was noninferior to strict rate control in the prevention of
major cardiovascular events in patients with permanent AF.
Furthermore, for both patients and health care providers,
lenient rate control is more convenient, since fewer out-
patient visits and examinations are needed. The clinical
implications of RACE II are that lenient rate control may
be adopted as a ﬁrst-choice rate-control strategy in patients
with permanent AF. Neverthless, since the study was rel-
atively small, large scale studies have to reveal the long
term effect of lenient rate vs strict control in patients with
AF in more detail (presenter: Isabelle C. Van Gelder,
Groningen, The Netherlands).
SORT OUT III
Drug-eluting stents (DES) are widely used because, com-
pared with bare-metal stents, in-stent restenosis and the
need for repeat revascularization are reduced. But are there
clinically meaningful differences between DES? SORT
OUT III (The Danish Organization for Randomized Trials
with Clinical Outcome: efﬁcacy and safety of zotarolimus-
eluting and sirolimus-eluting coronary stents in routine
clinical care) was a multicenter, single-blind, randomized
Fig. 2 NAVIGATOR. Kaplan–Meier curves for three coprimary
outcomes [9]. a The incidence of diabetes, the coprimary outcome.
b The coprimary extended cardiovascular outcome, a composite of
death from cardiovascular causes, nonfatal myocardial infarction,
nonfatal stroke, hospitalization for heart failure, arterial revascular-
ization, or hospitalization for unstable angina. All P values are two-
sided. The vertical bars indicate 95% conﬁdence intervals
Fig. 3 RACE II. Kaplan–Meier estimates of the cumulative inci-
dence of the primary outcome, according to treatment group [12]. The
numbers at the end of the Kaplan–Meier curves is the estimated
cumulative incidence of the primary outcome at 3 years
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safety of the zotarolimus-eluting stent versus the sirolimus-
eluting stent in patients with chronic stable coronary artery
disease or acute coronary syndromes [13]. The primary
endpoint was a composite of cardiac death, myocardial
infarction, and target vessel revascularization. 2,332
patients were included (1,162 received zotarolimus-eluting
stents, 1,170 received sirolimus-eluting stents). In contrast
to many other studies, patients with complex lesions (e.g.,
bifurcations, ostial lesions, and chronic total occlusions)
were included. At 9 months, the primary endpoint had
occurred in a signiﬁcant higher proportion of patients
treated with the zotarolimus-eluting stent than those treated
with the sirolimus-eluting stent [72 (6%) vs. 34 (3%); HR
2.15, 95% CI 1.43–3.23; P = 0.0002; Table 2]. At
18-month follow-up, this difference was sustained [113
(10%) vs. 53 (5%); HR 2.19, 95% CI 1.58–3.04; P\
0.0001]. For patients receiving the zotarolimus-eluting
stent and those receiving the sirolimus-eluting stent, all-
cause mortality was similar at 9-month follow-up, but was
signiﬁcantly different at 18-month follow-up [51 (4%) vs.
32 (3%); HR 1.61, 95% CI 1.03–2.50; P = 0.035;
Table 2). The authors conclude that the sirolimus-eluting
stent is superior to the zotarolimus-eluting stent for patients
receiving routine clinical care. Differences in results
between this and previously published trials may be due to
the all-comers design of the current study and the fact that
it was powered to assess clinical endpoints (presenter:
Michael Maeng, Aarhus, Denmark).
Duration of dual antiplatelet therapy after implantation
of drug-eluting stents
Early discontinuation of dual antiplatelet therapy has been
identiﬁed as a risk factor for late stent thrombosis in
patients with drug-eluting stents (DES) [14]. The optimal
duration of dual antiplatelet therapy is unclear. The current
analysis merged data from two concurrent randomized,
clinical multicenter trials (REAL-LATE and ZEST-LATE)
[15]. A total of 2,701 patients who were event-free for at
least 12 months after DES implantation were randomly
assigned to receive clopidogrel plus aspirin or aspirin
alone. The median duration of follow-up was 19.2 months.
There was no signiﬁcant beneﬁt associated with clopido-
grel continuation (clopidogrel plus aspirin) as compared
Table 2 SORT OUT III: clinical outcomes [13]
Zotarolimus-eluting
stent (n = 1,162)
Sirolimus-eluting
stent (n = 1,170)
Hazard ratio
(95% CI)
P value
Events at 30 days
a
All-cause mortality 4 (\1%) 4 (\1%) 1.01 (0.25–4.02) 0.99
Cardiac death 4 (\1%) 4 (\1%) 1.01 (0.25–4.02) 0.99
Myocardial infarction 9 (1%) 2 (\1%) 4.53 (0.98–21.0) 0.053
Target vessel revascularization 10 (1%) 8 (1%) 1.26 (0.50–3.19) 0.63
Target lesion revascularization 8 (1%) 5 (\1%) 1.61 (0.53–4.92) 0.40
Events at 9 months
a
Composite endpoint
b 72 (6%) 34 (3%) 2.15 (1.43–3.23) 0.0002
All-cause mortality 25 (2%) 18 (2%) 1.40 (0.76–2.56) 0.28
Cardiac death 12 (1%) 6 (1%) 2.01 (0.76–5.36) 0.16
Myocardial infarction 18 (2%) 4 (\1%) 4.55 (1.54–13.4) 0.006
Target vessel revascularization 62 (5%) 28 (2%) 2.25 (1.44–3.51) 0.0004
Target lesion revascularization 50 (4%) 12 (1%) 4.25 (2.26–7.97) \0.0001
Events at 18 months
c
Composite endpointb 113 (10%) 53 (5%) 2.19 (1.58–3.04) \0.0001
All-cause mortality 51 (4%) 32 (3%) 1.61 (1.03–2.50) 0.035
Cardiac death 18 (2%) 12 (1%) 1.51 (0.73–3.14) 0.27
Myocardial infarction 24 (2%) 11 (1%) 2.22 (1.09–4.53) 0.029
Target vessel revascularization 92 (8%) 39 (3%) 2.42 (1.67–3.52) \0.0001
Target lesion revascularization 71 (6%) 20 (2%) 3.66 (2.23–6.01) \0.0001
Data are number of patients (%), unless otherwise indicated
a Cumulative occurrence
b Composite of major adverse cardiac events: cardiac death, myocardial infarction, and clinically driven target vessel revascularization
c Estimated cumulative occurrence
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12 months, in reducing the incidence of myocardial
infarction or death from cardiac causes (primary endpoint;
Fig. 4)[ 15]. However, in the dual-therapy group as com-
pared with the aspirin-alone group, there was a nonsignif-
icant increase in the composite risk of myocardial
infarction, stroke, or death from any cause (hazard ratio
1.73, 95% CI 0.99–3.00; P = 0.051) and the composite
risk of myocardial infarction, stroke, or death from any
cause (hazard ratio 1.84, 95% CI 0.99–3.45; P = 0.06;
Fig. 4). However, the study had insufﬁcient statistical
power to allow a ﬁrm conclusion regarding the safety of
clopidogrel discontinuation after 12 months. Additional
studies addressing the use of dual antiplatelet therapy after
implantation of DES are ongoing (presenter: Seung-Jung
Park, Seoul, South Korea).
DOSE
The ﬁeld of acute decompensated heart failure (ADHF)
is plagued by virtually no evidence-based therapy [16].
Even the use of loop diuretics, the main treatment option
in most patients in clinical routine, is not evidence gui-
ded in regard to dose and route of administration. Based
on observational data, many clinicians believe that high-
dose loop diuretic admitted as a bolus would cause more
kidney damage than lower dosages as a continuous
infusion. The DOSE (Diuretic Optimization Strategies
Evaluation) trial separately randomized its 308 predom-
inantly male patients with a prior diagnosis of chronic
heart failure and daily outpatient use of oral loop
diuretics (80–240 mg) for at least 1 month to receive
intravenous furosemide at ‘‘low’’ versus ‘‘high’’ doses
and in a continuous infusion versus a bolus every 12 h.
‘‘Low dose’’ corresponded to the patient’s oral dose, and
‘‘high dose’’ meant 2.5 times the oral dose. Patients
presenting with a low systolic blood pressure (below
90 mmHg) and the anticipated need for coronary angi-
ography were excluded. Symptoms as gauged by patient
global assessment score at 72 h, the primary efﬁcacy end
point, were not signiﬁcantly different between the inter-
mittent and continuous dosing groups (P = 0.47). The
high-dose strategy trended toward greater symptom
Fig. 4 Dual antiplatelet therapy. Cumulative incidence of the
primary end point and selected secondary end points, according to
treatment group [15]. Cumulative-incidence curves are shown for the
primary end point of myocardial infarction (MI) or death from cardiac
causes (a), death from any cause (b), deﬁnite stent thrombosis (c), and
the secondary composite end point of death from any cause, MI, or
stroke (d). P values were calculated with the use of the log-rank test
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difference in the primary safety endpoint, change of
serum creatinine after 72 h between all groups. The
secondary endpoints favored higher doses with no change
between bolus of continuous infusion with an increased
risk of worsening of renal function, deﬁned as a [3 mg/
dl rise in creatinine. Nevertheless, 60 days after inclu-
sion, renal dysfunction was similar in all treatment arms
but interestingly still higher compared to before the
episode of ADHF. Moreover, although not powered for
clinical events, there was no difference in re-hospital-
ization or death favoring any group. Therefore, the
authors conclude that bolus administration with higher
doses may be convenient, safe as well as efﬁcient in
patients with ADHF (presenter: Gary Michael Felker,
Durham, USA).
ASPIRE
The ASPIRE (Aliskiren Study in Post-MI Patients to
Reduce REmodeling) study addressed the use of the direct
renin inhibitor aliskiren as an add-on to conventional
therapy in patients post-myocardial infarction with low
ejection fraction. The authors included 820 patients and
randomized them to placebo or aliskiren (titrated up to
300 mg) for 36 weeks. The inclusion criteria selected
patients on an ARB or an ACE-I (but no patients on an
ARB combined with an ACE-I) after an acute myocardial
infarction within 7–42 days with an EF below 45%. There
was no signiﬁcant improvement in the primary endpoint,
the change in the LV endsystolic volume between placebo
and aliskiren (-3.5 ± 16.3 vs. -4.4 ± 16.8; P = 0.44)
after 36 weeks. Nevertheless, double RAAS inhibition
with aliskiren as an add-on on top of conventional therapy
increased the risk of adverse events signiﬁcantly with
increased renal dysfunction (creatinine [2 and \3 mg/dl,
3 vs. 10 patients; P = 0.09), hypotension and hyperka-
lemia (5 vs. 22 patients; P\0.001) although there was
no signiﬁcant change in serious adverse events (creatinine
above 3 mg/dl). The panel discussed a ‘‘worrysome trend
towards increased mortality in the aliskiren group’’
although this study was not powered to address clinical
outcome, as stressed by the main ASPIRE author Scott
Solomon. Nevertheless, while ongoing outcome studies
with aliskiren in patients with heart failure and diabetic
kidney disease are on their way to completion, this study
does not provide evidence for the use of aliskiren as an
add-on post-myocardial infarction. Moreover, it is in line
with other ﬁndings demonstrating increased adverse
events without additional beneﬁt after double RAAS
inhibition in the ONTARGET trial [17] (presenter: Scott
D. Solomon, Boston, USA).
STICH (substudy)
While the data of the original STICH (Surgical Treatment
for Ischemic Heart Failure) trial [18] showed no evidence
for a beneﬁt for additional surgical ventricular recon-
struction (SVR) during CABG for patients with ischemic
cardiomyopathy, this year a paired core laboratory studies
was presented to determine whether any magnitude of
postoperative change in LV ESVI might identify a sub-
group of CABG ? SVR patients who have increased sur-
vival when compared to patients undergoing CABG alone.
The analysis was limited to the 595 patients who had
accurate preoperative and 4-month postoperative measures
of their end-systolic volume. No signiﬁcant difference was
found comparing groups with preoperative endsystolic
volume index (ESVI) below 60, between 60 and 90 and
above 90 ml/m
2. Many surgeons assumed that patients
whose baseline end-systolic volume index was especially
high ([90 ml/m
2) would beneﬁt most from SVR, the
STICH author Dr Robert Michler said. However, this
analysis found the opposite with a nonsigniﬁcant trend for
improvement in patients with relatively small ventricle
(group below 60 ml/m
2). Therefore, SVR seems to be no
option for general CABG surgery (presenter: Robert E.
Michler, Durham, USA).
CSP-474
The left internal mammary artery has been demonstrated to
be superior to the saphenous vein for coronary artery
bypass graft (CABG) procedures. The patency of radial-
artery grafts is unclear. CSP-474 was a prospective, ran-
domized, multicenter-study to compare the patency of
radial-artery grafts with saphenous-vein grafts. 733 patients
were enrolled in 11 VA medical centers between 2003 and
2008. Follow-up coronary artery angiography demon-
strated a 1-week patency of 99% for the radial-artery graft
and 97% for the venous graft. After 1 year, the patency for
both types of grafts was 89%. An analysis based on loca-
tion of the graft showed no differences based on what type
of graft was used. Of note, radial grafts were more likely
than saphenous grafts to show early signs of disease, with
8% of radial grafts showing the ‘‘string sign’’ compared
with just 1% of saphenous grafts. A subanalysis looking at
the low numbers of patients treated off-pump hinted that
patency was no different in radial grafts placed on- or off-
pump; by contrast, patency rates were lower in saphenous
grafts placed off-pump. And in another intriguing ﬁnding,
endoscopic harvesting—which has previously been linked
to worse patency—was linked to worse patency in the
saphenous grafts, but not in the radial grafts. A cost anal-
ysis showed that, overall, costs were nearly identical
Clin Res Cardiol (2010) 99:337–344 343
123between the two groups, at around $42,000 to $43,000.
Surgical costs, however, were slightly higher in the radial
group. In conclusion, there were no differences in the
radial-artery graft versus saphenous-vein grafts at 1 year.
However, since cardiac surgery is a treatment used for a
long-term outcome, it is necessary to look at long-term
patency (presenter: Steve Goldmann, Tucson, USA).
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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